iShares US Pharmaceuticals ETF
137 hedge funds and large institutions have $422M invested in iShares US Pharmaceuticals ETF in 2023 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 42 increasing their positions, 27 reducing their positions, and 13 closing their positions.
261% more capital invested
Capital invested by funds: $117M → $422M (+$305M)
104.09% more ownership
Funds ownership: 100.18% → 204.27% (+104%)
85% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 13
56% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 27
7% more funds holding
Funds holding: 128 → 137 (+9)
Top Buyers
| 1 |
Fisher Asset Management
Camas,
Washington
|
+$209M |
| 2 |
Morgan Stanley
New York
|
+$55.8M |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$7.31M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$6.44M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$3.94M |
Top Sellers
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.66M |
| 2 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$2.29M |
| 3 |
MFG
Merit Financial Group
Alpharetta,
Georgia
|
-$1.84M |
| 4 |
Goldman Sachs
New York
|
-$1.78M |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$1.39M |
IHE Hedge Fund Activity: Q4 2023 in Review
137 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q4 2023, worth a combined $422M — up 261% from $117M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new IHE positions and 13 closed out — a net gain of 11 holders — while 42 added to existing stakes and 27 trimmed.
The largest buyer was Fisher Asset Management, adding an estimated $209M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $3.66M sold.
- 137 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q4 2023, up from 128 in Q3 2023.
- Funds reported $422M of iShares US Pharmaceuticals ETF stock for Q4 2023, up 261% quarter-over-quarter.
- 24 funds opened new iShares US Pharmaceuticals ETF positions in Q4 2023 and 13 closed out, a net change of +11 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q4 2023 was Fisher Asset Management, an estimated $209M added.
- The largest iShares US Pharmaceuticals ETF seller in Q4 2023 was Susquehanna International Group, an estimated $3.66M sold.
Based on aggregated 13F filings for Q4 2023.